Skip to main content
. 2012 Mar;97(3):388–392. doi: 10.3324/haematol.2011.051532

Figure 1.

Figure 1

Kaplan-Meier survival analyses of patients with AML with or without ASXL1 mutations. (A) OS for all AML patients (<65 years). (B) RFS for all AML patients (<65 years). (C) OS for patients with intermediate-risk AML. (D) OS for patients with intermediate-risk and FLT3wt and NPM1wt. Survival curves in red refer to cases with ASXL1mut; those in green to ASXL1wt. The log rank P value is indicated per Kaplan-Meier analysis.